Baker discusses menopause-related sleep disturbances and why early screening and individualized treatment are critical in primary care.
In an interview ahead of the meeting, Baker emphasized that clinicians should routinely ask midlife patients about sleep, rather than waiting for patients to volunteer concerns. She noted that more than 60% of women experience sleep disturbances during menopause, particularly difficulty staying asleep and returning to sleep after nighttime awakenings, and that these disruptions carry implications well beyond nighttime discomfort. Difficulty maintaining sleep, particularly nocturnal awakenings with inability to return to sleep, is among the most common presenting complaints in this population, and the downstream effects on cardiovascular health, mood, and cognitive function make early identification a clinical priority.
Vasomotor symptoms such as hot flashes and night sweats are well-established contributors to menopausal sleep disruption, but Baker emphasized clinicians should not anchor too narrowly on this link. Sleep disturbances may present as the primary complaint without a clear vasomotor driver, and may emerge as early as perimenopause, before women or their providers have connected the changes to the menopausal transition.
Baker also underscored the importance of early intervention. Evidence from insomnia research more broadly supports earlier treatment as a predictor of better and faster outcomes, and this principle applies directly to menopause-related sleep problems. Cognitive behavioral therapy for insomnia (CBT-I) remains the gold-standard treatment when insomnia is the primary complaint, and several pharmacological options are also available for managing menopausal symptoms contributing to sleep disruption.
Determining whether sleep disturbance in a midlife patient is driven primarily by the menopausal transition or by other overlapping factors requires a structured clinical inquiry. Baker outlined key considerations: the timing of sleep symptom onset relative to menopausal stage, the presence and subjective impact of vasomotor symptoms, mood and psychosocial stressors, and screening for primary sleep disorders such as obstructive sleep apnea or restless legs syndrome.
No single factor operates in isolation. Because multiple contributors may be active simultaneously in any given patient, Baker advocated for an individualized treatment approach calibrated to the specific pattern of drivers present rather than a one-size-fits-all protocol. That begins, she noted, simply with asking the question.
Editors’ note: Baker reports relevant disclosures with Bayer.
